John Townsend
Equibles does not estimate personal net worth.
Get an email with a short summary when Unicycive Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get UNCY alertsAbout John Townsend
John Townsend is recorded as CFO at Unicycive Therapeutics, Inc. (UNCY). The newest filing on record that lists John Townsend as CFO at Unicycive Therapeutics, Inc. (UNCY) is dated April 30, 2026. Earlier roles on record: CFO at Ribbon Communications Inc. (RBBN) until April 30, 2026. Ribbon Communications Inc. reported in an 8-K filed April 28, 2026 that John Townsend resigned as Executive Vice President, Chief Financial Officer, effective April 30, 2026. The proxy statement of Unicycive Therapeutics, Inc. reports total compensation of $383,117 for John Townsend in fiscal 2021, including a base salary of $91,667. Disclosed compensation is on record for 2 fiscal years. John Townsend has spoken on 6 earnings calls across 1 company, most recently for Ribbon Communications Inc. on April 28, 2026. Unicycive Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls John Townsend spoke on are classified in the Technology sector. Other leadership on record at Unicycive Therapeutics, Inc. includes Shalabh Gupta (CEO and Board Member), Gaurav Aggarwal, M.D. (Board Member), Gaurav Aggarwal, MD (Board Member) and 1 other.
“On April 28, 2026, Ribbon Communications Inc. (the "Company") announced that John Townsend, Executive Vice President, Chief Financial Officer of the Company, has notified the Company that he is resigning effective April 30, 2026 to pursue another professional opportunity.”
John Townsend on recent calls
“Let's begin with financial results at a consolidated level. In the first quarter of 2026, Ribbon generated revenues $163 million, a decrease of 10% in the prior year, driven by the factors Bruce outlined and which I will touch on shortly in the segmental discussion.”
“It was also impacted by geographic mix, with a very strong performance from our team in India. For the full year, non-GAAP gross margin was 52.3%, down 355 basis points from the prior year, driven by the higher sales in India and the higher services revenues.”
“Let's begin with Q3 financial results at the consolidated level. We generated revenues of $215 million in the quarter, an increase of 2% from the prior year, within the guidance range we discussed during our Q2 earnings call.”
“Let's begin with Q2 financial results at the consolidated level.”
“Let's begin with financial results at the consolidated level. In the first quarter of 2025, Ribbon generated revenues of $181 million, an increase of 1% from the prior year.”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 30, 2026
-
Start not stated–2026-04-30
Company network
Software - Application · Technology
CFO
Leadership on record at Unicycive Therapeutics, Inc.
- Shalabh Gupta CEO, Board Member
- Gaurav Aggarwal, M.D. Board Member
- Gaurav Aggarwal, MD Board Member
- Meredith S. Manning Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Unicycive Therapeutics, Inc. (UNCY) | CPA, Chief Financial Officer | $91,667 | $383,117 |
| 2020 | Unicycive Therapeutics, Inc. (UNCY) | CPA, Chief Financial Officer | — | $39,750 |